Plant Comparison
Andrographis vs Goldenseal
A side-by-side comparison of two medicinal plants — every documented constituent, action, use, safety note and cited source, assembled automatically from the Omnia Sana database.
At a glance
Andrographis and Goldenseal: they share 6 indicated uses (arthritis / joint pain, infection (general), inflammation (general), …); 2 pharmacological actions in common.
Evidence face-off — shared uses
| Condition | Andrographis | Goldenseal | Verdict |
|---|---|---|---|
| Arthritis / joint pain | 5/10 | 5/10 | Comparable evidence |
| Infection (general) | 8/10 | 5/10 | Stronger for Andrographis |
| Inflammation (general) | 5/10 | 5/10 | Comparable evidence |
| Skin irritation | 5/10 | 5/10 | Comparable evidence |
| Sore throat | 7/10 | 5/10 | Stronger for Andrographis |
| Wounds | 5/10 | 5/10 | Comparable evidence |
Evidence scores (1–10) are computed from the tier of each cited source. “Comparable” means the two scores are within one point. Follow a score to its detailed sources.
Key Constituents
Berberine is the main antimicrobial, hypoglycaemic and hypolipidaemic constituent. Notably, whole-leaf extracts are more potent against MRSA than isolated berberine (owing to efflux-pump-inhibitory flavonoids) and show quorum-quenching, anti-virulence activity.
Pharmacological Actions
Andrographolide, the principal diterpene lactone of Andrographis paniculata, suppresses proliferation and induces apoptosis across breast, lung, colon, cervical, hepatic and haematological cancers via NF-kappaB and PI3K/Akt inhibition (preclinical).
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth)
Traditional & Indicated Uses
inferred from anti-inflammatory action
Andrographolide (from Andrographis paniculata) acts as a chemopreventive and antitumour agent against breast, lung, colorectal, cervical, prostate and hepatocellular cancers and leukaemia, inducing apoptosis and inhibiting NF-kappaB and PI3K/AKT signalling (preclinical).
Symptomatic relief of the common cold and acute upper respiratory tract infection (reduces symptom severity and duration)
Immunostimulant / immune support
Symptomatic relief of the common cold and acute upper respiratory tract infection (reduces symptom severity and duration)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Digestive / gastrointestinal support (traditional for dyspepsia and ulcers)
Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat; Topical for skin infections and irritation - whole-leaf extract is active in vitro against methicillin-resistant Staphylococcus aureus (MRSA)
inferred from anti-inflammatory action
inferred from anti-inflammatory action
Anti-inflammatory and astringent for inflamed mucous membranes (sore-throat gargle, mouth); Antimicrobial (berberine) - supports skin, mucosal and gastrointestinal infections and sore throat
Safety, Cautions & Contraindications
Avoid in pregnancy and when trying to conceive: high doses have shown reproductive toxicity in animals and the herb has a traditional reputation as an abortifacient.
High doses have caused nephrotoxicity and reproductive toxicity in studies; use standardized products at recommended doses and avoid prolonged high-dose use.
Contraindicated in pregnancy and breastfeeding: berberine crosses the placenta and into milk and can cause or worsen newborn jaundice (risk of kernicterus); do not give to infants.
Berberine strongly inhibits drug-metabolising enzymes (especially CYP3A4 and CYP2D6), so it can raise the blood levels of many medicines - a significant herb-drug-interaction risk. In a screen of commercial herbal products, goldenseal was among the most potent CYP2D6 inhibitors and also inhibited CYP3A4. High doses have shown possible liver, nerve and photo-toxicity.
External Ids
Botanical Description
Erect, branching annual herb with a slender, quadrangular (square-sectioned), dark green stem. The leaves are opposite, lance-shaped and glabrous, with a short stalk. Small, two-lipped, white flowers with purple-pink markings are borne in loose, spreading axillary and terminal racemes. The whole plant, and especially the leaves, is intensely and characteristically bitter.[11]
Low, woodland perennial herb rising from a knotted, bright yellow rhizome with wiry yellow roots. Each stem bears two ragged, palmately lobed, maple-like leaves and a single small, inconspicuous greenish-white flower, followed by a raspberry-like cluster of red berries.[1]
Habitat
Native to India and Sri Lanka and widely distributed through South and Southeast Asia, growing wild in plains, hillsides, roadsides and cultivated fields; also grown commercially as a medicinal crop.[11]
Grows in rich, shaded deciduous woodland with humus-rich soil; native to eastern North America, now scarce in the wild due to overharvesting and largely supplied by cultivation.[1]
Harvesting
The aerial parts (leaves and tender stems) are cut just before or at the onset of flowering, when andrographolide content is typically highest, and dried in shade to preserve the bitter diterpenoid lactones.[11]
The rhizome and root are dug in autumn from plants at least three to four years old, when berberine content is highest, then cleaned and dried; because wild populations are depleted, cultivated or sustainably sourced material is strongly preferred, and careful identification against the toxic mayapple and bloodroot, which share its woodland habitat, is essential before any wild-harvesting.[1]
Traditional Uses
Andrographis, the 'king of bitters', is a cornerstone bitter tonic of Ayurvedic and traditional Chinese medicine (Chuan xin lian), used for fevers, colds, sore throat, infections and liver complaints. This traditional reputation for treating the common cold and upper respiratory infections is now supported by clinical trials of standardised extracts.[10, 12]
Goldenseal root has a Native American and, after adoption by Eclectic physicians, wider North American tradition as a bitter tonic and antimicrobial remedy for mucous-membrane infections, sore throat, digestive upset and topical skin infections, directly reflecting its high berberine content.[1]
Preparations
Dried aerial parts infused or lightly decocted in hot water as a very bitter traditional fever and cold remedy.
Dried rhizome and root simmered in water as a traditional bitter antimicrobial tea, or used as a gargle for sore throat.
Tincture 1:10 in 60% ethanol of the dried rhizome and root, 2-4 ml three times daily per the WHO monograph Rhizoma Hydrastis. Educational reference only, not a prescription.
Extract standardised to berberine/hydrastine content, taken as capsules; whole-leaf extracts have shown stronger antimicrobial activity than isolated berberine in some studies.
Dosage
Clinical trials for upper respiratory infection commonly use extracts standardised to around 60-120 mg andrographolide daily, in divided doses, for up to 5-7 days. Educational reference only, not a prescription.
The WHO monograph on Herba Andrographidis gives, by indication - for the common cold, 1.5-3.0 g of the powdered crude drug three times daily, after meals and at bedtime; for pyrexia, a decoction from 3 g of the crude drug twice daily; for diarrhoea, a decoction from 3-9 g as a single dose as needed, or two 500 mg tablets four times daily. Note that the EMA HMPC assessed this herb and issued a public statement rather than a monograph, so there is no EU posology. Educational reference only, not a prescription.
The WHO monograph on Rhizoma Hydrastis gives a daily dose of 0.5-1.0 g of the dried rhizome and root three times, or taken as a decoction; a 1:1 liquid extract in 60% ethanol at 0.3-1.0 mL three times; or a 1:10 tincture in 60% ethanol at 2-4 mL three times. For short-term use only, given goldenseal's potent CYP-enzyme inhibition and its contraindication in pregnancy. Educational reference only, not a prescription.
References
Lookalikes Review
Drug Class Interactions
Not documented
Dangerous Lookalikes
Not documented
References & Sources
- Okonogi, R. and others (2023) 'Efficacy of Andrographis paniculata spray in acute pharyngitis: A randomized controlled trial', Drug Discoveries & Therapeutics, 17(5), pp. 315-321. doi:10.5582/ddt.2023.01053 Randomized trial
https://doi.org/10.5582/ddt.2023.01053 - Hossain, S., Urbi, Z., Karuniawati, H., Mohiuddin, R.B. and others (2018) 'Overview of pharmacological activities of Andrographis paniculata and its major compound andrographolide', Critical Reviews in Food Science and Nutrition, 61(10), pp. 1635-1652. doi:10.1080/10408398.2018.1501657 Meta-analysis / review
https://doi.org/10.1080/10408398.2018.1501657 - Worakunphanich, W. and others (2021) 'Andrographis paniculata Formulations: Impact on Diterpene Lactone Oral Bioavailability', European Journal of Drug Metabolism and Pharmacokinetics, 46(5), pp. 565-581. doi:10.1007/s13318-021-00736-7 Meta-analysis / review
https://doi.org/10.1007/s13318-021-00736-7 - Worakunphanich, W., Thavorncharoensap, M., Youngkong, S., Thakkinstian, A. and Chaikledkaew, U (2021) 'Safety of Andrographis paniculata: A systematic review and meta-analysis', Pharmacoepidemiology and Drug Safety, 30(6), pp. 727-739. doi:10.1002/pds.5190 Meta-analysis / review
https://doi.org/10.1002/pds.5190 - Kumar, S., Singh, B. and Bajpai, V (2021) 'Andrographis paniculata (Burm.f.) Nees and its major constituent andrographolide as potential antiviral agents', Journal of Ethnopharmacology, 274, pp. 113954. doi:10.1016/j.jep.2021.113954 Meta-analysis / review
https://doi.org/10.1016/j.jep.2021.113954 - Barbosa, F.L. and others (2021) 'Andrographis paniculata (Burm. f.) Wall. ex Nees: An Updated Review of Phytochemistry, Antimicrobial Pharmacology, and Clinical Safety and Efficacy', Life, 11(4), pp. 348. doi:10.3390/life11040348 Meta-analysis / review
https://doi.org/10.3390/life11040348 - Singh, P. and others (2022) 'Andrographis paniculata mitigates first-line anti-tubercular drugs-induced nephrotoxicity in Wistar rats', Biomarkers, 27(4), pp. 385-394. doi:10.1080/1354750X.2022.2043444 Preclinical
https://doi.org/10.1080/1354750X.2022.2043444 - Coon, J.T. and Ernst, E (2004) 'Andrographis paniculata in the symptomatic treatment of uncomplicated upper respiratory tract infection: systematic review of randomized controlled trials', Journal of Clinical Pharmacy and Therapeutics, 29(1), pp. 37-45. doi:10.1046/j.1365-2710.2003.00534.x Meta-analysis / review
https://doi.org/10.1046/j.1365-2710.2003.00534.x - Rondee, N. and others (2023) 'The Effects of Andrographis paniculata (Burm.F.) Wall. Ex Nees and Andrographolide on Neuroinflammation in the Treatment of Neurodegenerative Diseases', Nutrients, 15(15), pp. 3428. doi:10.3390/nu15153428 Meta-analysis / review
https://doi.org/10.3390/nu15153428 - Zeng, B., Wei, A., Zhou, Q., Yuan, M., Lei, K., Liu, Y., Song, J., Guo, L. and Ye, Q (2021) 'Andrographolide: A review of its pharmacology, pharmacokinetics, toxicity and clinical trials and pharmaceutical researches', Phytotherapy Research. doi:10.1002/ptr.7324 Randomized trial
https://doi.org/10.1002/ptr.7324 - Gonde, D.P., Bhole, B.K. and Kakad, K.S (2023) 'Andrographolide, diterpenoid constituent of Andrographis paniculata: Review on botany, phytochemistry, molecular docking analysis, and pharmacology', Annales Pharmaceutiques Francaises. doi:10.1016/j.pharma.2023.10.001 Preclinical
https://doi.org/10.1016/j.pharma.2023.10.001 - Hu, X.Y., Wu, R.H., Logue, M., Blondel, C., Lai, L.Y.W., Stuart, B., Flower, A., Fei, Y.T., Moore, M., Shepherd, J., Liu, J.P. and Lewith, G (2017) 'Andrographis paniculata (Chuan Xin Lian) for symptomatic relief of acute respiratory tract infections in adults and children: A systematic review and meta-analysis', PLoS ONE. doi:10.1371/journal.pone.0181780 Meta-analysis / review
https://doi.org/10.1371/journal.pone.0181780 - World Health Organization (2002) 'Herba Andrographidis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Tundis, R. and Patra, J.K. and Bonesi, M. and Das, S. and Nath, R. and Das Talukdar, A. and Das, G. and Loizzo, M.R (2023) 'Anti-Cancer Agent: The Labdane Diterpenoid-Andrographolide', Plants, 12(10), pp. 1969. doi:10.3390/plants12101969 Preclinical
https://doi.org/10.3390/plants12101969 - Mishra, S.K. and Tripathi, S. and Shukla, A. and Oh, S.H. and Kim, H.M (2015) 'Andrographolide and analogues in cancer prevention', Frontiers in Bioscience (Elite Edition), 7(2), pp. 255-266. doi:10.2741/E732 Preclinical
https://doi.org/10.2741/E732 - Paul, S. and Roy, D. and Pati, S. and Sa, G (2021) 'The Adroitness of Andrographolide as a Natural Weapon Against Colorectal Cancer', Frontiers in Pharmacology, 12, pp. 731492. doi:10.3389/fphar.2021.731492 Preclinical
https://doi.org/10.3389/fphar.2021.731492 - Memorial Sloan Kettering Cancer Center (n.d.) 'Andrographis (About Herbs)'. Available at: https://www.mskcc.org/cancer-care/integrative-medicine/herbs/andrographis Traditional / reference
https://www.mskcc.org/cancer-care/integrative-medicine/herbs/andrographis
- Mandal, S.K., Maji, A.K., Mishra, S.K., Ishfaq, P.M., Devkota, H.P., Silva, A.S. and Das, N (2020) 'Goldenseal (Hydrastis canadensis L.) and its active constituents: A critical review of their efficacy and toxicological issues', Pharmacological Research. doi:10.1016/j.phrs.2020.105085 Randomized trial
https://doi.org/10.1016/j.phrs.2020.105085 - Corn, J., Tibbitts, D., Ito, H., Schafer, M. and Vasilevsky, N (2021) 'Effects of Hydrastis Canadensis, Commiphora Habessinica, Phytolacca Americana, and Echinacea Purpurea on Bacterial Growth', Alternative Therapies in Health and Medicine, 27(4), pp. 24-27. Preclinical
https://scholar.google.com/scholar?q=Effects%20of%20Hydrastis%20Canadensis%2C%20Commiphora%20Habessinica%2C%20Phytolacca%20Americana%2C%20and%20Echinacea%20Purpurea%20on%20Bacterial%20Growth - Ettefagh, K.A., Burns, J.T., Junio, H.A., Kaatz, G.W. and Cech, N.B (2010) 'Goldenseal (Hydrastis canadensis L.) extracts synergistically enhance the antibacterial activity of berberine via efflux pump inhibition', Planta Medica, 77(8), pp. 835-840. doi:10.1055/s-0030-1250606 Preclinical
https://doi.org/10.1055/s-0030-1250606 - Cech, N.B., Junio, H.A., Ackermann, L.W., Kavanaugh, J.S. and Horswill, A.R (2012) 'Quorum quenching and antimicrobial activity of goldenseal (Hydrastis canadensis) against methicillin-resistant Staphylococcus aureus (MRSA)', Planta Medica, 78(14), pp. 1556--1561. doi:10.1055/s-0032-1315042 Traditional / reference
https://doi.org/10.1055/s-0032-1315042 - Mahady, G.B., Pendland, S.L., Stoia, A. and Chadwick, L.R (2003) 'In vitro susceptibility of Helicobacter pylori to isoquinoline alkaloids from Sanguinaria canadensis and Hydrastis canadensis', Phytotherapy Research, 17(3), pp. 217-221. doi:10.1002/ptr.1108 Preclinical
https://doi.org/10.1002/ptr.1108 - Junio, H.A., Sy-Cordero, A.A., Ettefagh, K.A., Burns, J.T., Micko, K.T., Graf, T.N., Richter, S.J., Cannon, R.E., Oberlies, N.H. and Cech, N.B (2011) 'Synergy-directed fractionation of botanical medicines: a case study with goldenseal (Hydrastis canadensis)', Journal of Natural Products, 74(7), pp. 1621-1629. doi:10.1021/np200336g Preclinical
https://doi.org/10.1021/np200336g - Britton, E.R., Kellogg, J.J., Kvalheim, O.M. and Cech, N.B (2017) 'Biochemometrics to Identify Synergists and Additives from Botanical Medicines: A Case Study with Hydrastis canadensis (Goldenseal)', Journal of Natural Products, 81(3), pp. 484-493. doi:10.1021/acs.jnatprod.7b00654 Preclinical
https://doi.org/10.1021/acs.jnatprod.7b00654 - Leyte-Lugo, M., Britton, E.R., Foil, D.H., Brown, A.R., Todd, D.A., Rivera-Chavez, J., Oberlies, N.H. and Cech, N.B (2017) 'Secondary Metabolites from the Leaves of the Medicinal Plant Goldenseal (Hydrastis canadensis)', Phytochemistry Letters, 20, pp. 54-60. doi:10.1016/j.phytol.2017.03.012 Preclinical
https://doi.org/10.1016/j.phytol.2017.03.012 - Gurley, B.J., Swain, A., Hubbard, M.A., Hartsfield, F., Thaden, J., Williams, D.K., Gentry, W.B. and Tong, Y (2007) 'Supplementation with goldenseal (Hydrastis canadensis), but not kava kava (Piper methysticum), inhibits human CYP3A activity in vivo', Clinical Pharmacology and Therapeutics, 83(1), pp. 61-69. doi:10.1038/sj.clpt.6100222 Randomized trial
https://doi.org/10.1038/sj.clpt.6100222 - Wallace, E.D., Oberlies, N.H., Cech, N.B. and Kellogg, J.J (2018) 'Detection of adulteration in Hydrastis canadensis (goldenseal) dietary supplements via untargeted mass spectrometry-based metabolomics', Food and Chemical Toxicology, 120, pp. 439-447. doi:10.1016/j.fct.2018.07.033 Preclinical
https://doi.org/10.1016/j.fct.2018.07.033 - Douglas, J.A., Follett, J.M., Parmenter, G.A., Sansom, C.E., Perry, N.B. and Littler, R.A (2010) 'Seasonal variation of biomass and bioactive alkaloid content of goldenseal, Hydrastis canadensis', Fitoterapia, 81(7), pp. 925-928. doi:10.1016/j.fitote.2010.06.006 Preclinical
https://doi.org/10.1016/j.fitote.2010.06.006 - Singh, S., Pathak, N., Fatima, E. and Negi, A.S (2021) 'Plant isoquinoline alkaloids: Advances in the chemistry and biology of berberine', European Journal of Medicinal Chemistry. doi:10.1016/j.ejmech.2021.113839 Preclinical
https://doi.org/10.1016/j.ejmech.2021.113839 - World Health Organization (2007) 'Rhizoma Hydrastis'. Available at: https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 Traditional / reference
https://iris.who.int/items/6418d8af-5200-4e6b-9bf5-004f3aa62a37 - Sevior, D.K., Hokkanen, J., Tolonen, A., Abass, K., Tursas, L., Pelkonen, O. and Ahokas, J.T (2010) 'Rapid screening of commercially available herbal products for the inhibition of major human hepatic cytochrome P450 enzymes using the N-in-one cocktail', Xenobiotica, 40(4), pp. 245--254. doi:10.3109/00498251003592683 Preclinical
https://doi.org/10.3109/00498251003592683 - Gurley, B.J., Gardner, S.F., Hubbard, M.A., Williams, D.K., Gentry, W.B., Khan, I.A. and Shah, A (2005) 'In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes', Clinical Pharmacology and Therapeutics, 77(5), pp. 415-426. doi:10.1016/j.clpt.2005.01.009 Randomized trial
https://doi.org/10.1016/j.clpt.2005.01.009 - McDonald, M.G., Tian, D.D., Thummel, K.E., Paine, M.F. and Rettie, A.E (2020) 'Modulation of major human liver microsomal cytochromes P450 by component alkaloids of goldenseal: time-dependent inhibition and allosteric effects', Drug Metabolism and Disposition, 48(10), pp. 1018-1027. doi:10.1124/dmd.120.091041 Preclinical
https://doi.org/10.1124/dmd.120.091041 - Guo, J., Chen, H., Zhang, X., Lou, W., Zhang, P., Qiu, Y., Zhang, C., Wang, Y. and Liu, W.J (2021) 'The effect of berberine on metabolic profiles in type 2 diabetic patients: a systematic review and meta-analysis of randomized controlled trials', Oxidative Medicine and Cellular Longevity, 2021, pp. 2074610. doi:10.1155/2021/2074610 Meta-analysis / review
https://doi.org/10.1155/2021/2074610 - Forest Farming (Cooperative Extension) 'Goldenseal (Hydrastis canadensis L.)'. Available at: https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ Traditional / reference
https://forest-farming.extension.org/goldenseal-hydrastis-canadensis-l/ - Frasca, T. and Brett, A.S. and Yoo, S.D (1997) 'Mandrake toxicity. A case of mistaken identity', Archives of Internal Medicine, 157(17), pp. 2007-9. doi:10.1001/archinte.157.17.2007 Clinical study
https://doi.org/10.1001/archinte.157.17.2007 - North Carolina Extension Gardener Plant Toolbox 'Sanguinaria canadensis (Bloodroot)'. Available at: https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/ Traditional / reference
https://plants.ces.ncsu.edu/plants/sanguinaria-canadensis/
Generated automatically from the Omnia Sana plant database and its cited sources. For educational purposes only — not medical advice. Always consult a qualified practitioner before using medicinal plants.